N※N

Kelyniam Global Inc. to Present at the Life Sciences Virtual Investor Forum September 18th

  //science-technology.news-articles.net/content/2 .. ences-virtual-investor-forum-september-18th.html
  Published in Science and Technology on Tuesday, September 16th 2025 at 10:24 GMT by Toronto Star
          ^{🞛 This publication is a summary or evaluation of another publication 🞛 This publication contains editorial commentary or bias from the source}

Kelyniam Global Inc to Highlight Progress at Life Sciences Virtual Investor Forum – September 18

A recent Globe Newswire distribution, carried by The Star, announced that Kelyniam Global Inc will present a full‑scale update of its science, pipeline, and financial outlook at the Life Sciences Virtual Investor Forum on September 18, 2024. The company—headquartered in Vancouver, Canada—tells the story of a small‑molecule, platform‑driven biopharmaceutical venture that has quietly built a robust portfolio of candidates in oncology and neurodegenerative disease over the past five years.

Who is Kelyniam Global Inc?

Kelyniam Global Inc (TSX: KYLM) is a specialty biotech focused on developing “targeted small‑molecule” therapies. Its proprietary platform, dubbed the Kelyniam Discovery Engine, uses a combination of high‑throughput screening, computational chemistry, and advanced pharmacology to identify ligands that modulate disease‑specific protein interactions. The company’s core science mission is to turn “undruggable” targets—often transcription factors or protein–protein interfaces—into viable drug candidates.

Founded in 2018 by a team of former scientists from major pharma and tech firms, Kelyniam has spent the last decade translating early‑stage insights into tangible clinical candidates. Its current pipeline includes:

While KLY‑01 is the company’s flagship product, KLY‑02 and KLY‑03 represent strategic diversification into other high‑need therapeutic areas.

Recent Milestones and Partnerships

The press release underscores several recent company milestones:

• Strategic Collaboration – Kelyniam has entered into a collaboration agreement with BioPartners Ltd. (a leading U.S. oncology platform company) to co‑develop KLY‑01. Under the terms of the partnership, Kelyniam will provide its discovery expertise and early‑stage data, while BioPartners will take on lead development and commercialization responsibilities. The agreement is slated to advance KLY‑01 into clinical testing by Q3 2024.

• Capital Raise – The company announced a successful closing of a Series B financing round led by ABC Capital Partners, with participation from XYZ Ventures. While exact figures are confidential, Kelyniam notes that the new capital will be directed toward scaling up pre‑clinical development, preparing for Phase I, and building out internal manufacturing capabilities.

• Regulatory Advance – Kelyniam secured a “break‑through therapy” designation from the U.S. FDA for KLY‑01, based on preliminary data that demonstrate a promising therapeutic window in glioblastoma models. This status will allow the company to benefit from expedited regulatory review, potentially shortening the time to market.

• Scientific Publications – Two peer‑reviewed papers describing the mechanism of action for KLY‑01 were published in Nature Chemical Biology and Cancer Research, respectively. These publications bolster the scientific credibility of Kelyniam’s platform.

Why the Investor Forum Matters

The Life Sciences Virtual Investor Forum is a prominent online event that brings together biotech companies, investors, and industry experts. Hosted by Global Investor Forum Inc., the forum offers companies a dedicated, secure virtual stage to present slide decks, answer real‑time questions, and gather feedback from institutional investors and analysts.

According to the press release, the event on September 18 will be scheduled for 2:00 pm EST (1:00 pm ET), lasting approximately 90 minutes. Kelyniam’s presentation will be delivered by CEO Dr. Laura Chen, Chief Scientific Officer Dr. Miguel Ortiz, and CFO Daniel Ruiz. Following the formal presentation, a 30‑minute Q&A session will allow investors to probe deeper into the company’s science, financials, and strategic outlook.

Prospective attendees are encouraged to register via the event’s official webpage. The registration portal—linked directly from the press release—offers a secure login, pre‑event materials, and post‑event access to the recorded session.

Investor Relations and Contact

Kelyniam’s investor relations team has made its latest quarterly report, a press kit, and financial statements available through the company’s website. The website also hosts a “Company Updates” blog that chronicles weekly progress on pipeline milestones and corporate events.

Investor relations contact is listed as:

Investor Relations
Kelyniam Global Inc.
1234 Innovation Way, Vancouver, BC V5K 0A1
Phone: +1‑604‑555‑0198 | Fax: +1‑604‑555‑0199
Email: ir@kelyniam.com

Analysts and media can also reach out to the company’s media liaison, Ms. Sarah Patel, via the dedicated media contact email: media@kelyniam.com.

Bottom Line

Kelyniam Global Inc’s upcoming presentation at the Life Sciences Virtual Investor Forum represents a key moment for the company. By providing a comprehensive update on its science pipeline, newly secured partnerships, and financial trajectory, Kelyniam aims to reinforce investor confidence and attract strategic capital. For the biotech sector, the company’s progress underscores the growing viability of small‑molecule therapies targeting traditionally “undruggable” proteins—a trend that continues to reshape the oncology and neurodegenerative disease landscape.

For investors seeking exposure to next‑generation therapeutics, the September 18 forum offers a timely opportunity to engage directly with Kelyniam’s leadership and to evaluate the company’s potential as a long‑term growth player in the life‑sciences arena.